No­var­tis just boast­ed of a big PhI­II PI3K suc­cess, but here’s why we should hold our ap­plause — for now

7 years ago
R&D

Mag­ic mush­rooms might treat de­pres­sion? Pe­ter Thiel-backed Com­pass gets FDA OK to launch Phase IIb tri­als

7 years ago
Startups

Os­teoarthri­tis: FDA drafts guid­ance on de­vel­op­ing drugs, de­vices, bi­o­log­ics

7 years ago
Pharma

Pfiz­er inks mar­ket­ing deal for col­orec­tal can­cer test; Zai Lab dous­es a hot ru­mor about a Hong Kong IPO

7 years ago
News Briefing

With Al­ler­gan's ri­val on the reg­u­la­to­ry ropes, Ab­b­Vie posts more promis­ing late-stage da­ta for elagolix

7 years ago
R&D

Jaun­dice drug for in­fants re­ject­ed by FDA, shak­ing up Mallinck­rodt's plans for new­ly-ac­quired stannso­porfin

7 years ago
R&D

Bris­tol-My­ers will sell Op­di­vo in Chi­na at half of US cost, set­ting prece­dent for check­point wave — re­port

7 years ago
China
Pharma

Re­mem­ber mo­melo­tinib? Gilead un­loads shelved JAK in­hibitor for to­ken $3M pay­ment from its for­mer de­vel­op­ers

7 years ago
Pharma

Costs ris­ing, As­traZeneca switch­es con­trac­tors and once again de­lays sched­uled com­ple­tion of its trou­bled $650M-plus ...

7 years ago
Pharma

No­vo Nordisk turns to Evotec to build ear­ly-stage pipeline for di­a­betes, obe­si­ty drugs

7 years ago
Pharma

$60M in, Ab­b­Vie is trig­ger­ing a $625M-plus plan to de­vel­op a new im­muno-on­col­o­gy drug that is go­ing af­ter GARP

7 years ago
Pharma

FDA turns thumbs down on Al­ler­gan's op­ti­mistic case for uter­ine fi­broid drug as liv­er dam­age threat tor­pe­does ...

7 years ago
R&D
Pharma

Shrink the pa­tient group, boost the ef­fi­ca­cy: Tonix says a retro look shows promise in se­lect PTSD group

7 years ago
R&D

Rex­ahn inks Keytru­da com­bo col­lab­o­ra­tion in breast can­cer; Achillion hires uniQure's Steven Ze­lenkofske as new CMO

7 years ago
News Briefing

A knock­down-and-re­place gene ther­a­py from Penn re­searchers shows promise in rare eye dis­ease

7 years ago
Cell/Gene Tx

As­traZeneca’s on­col­o­gy drug star Tagris­so gets a new ap­proval for front­line lung can­cer in Japan

7 years ago
Pharma

Con­struc­tion sources buzzing about a new set of headaches and hur­dles fac­ing As­traZeneca’s be­lea­guered, $650M HQ ...

7 years ago
Financing

Cam­bridge in­ves­ti­ga­tors ze­ro in on a new, niche drug tar­get for lung can­cer

7 years ago
Discovery

Come join me dur­ing my round-the-world biotech ad­ven­ture in Oc­to­ber, with events in Lon­don and Shang­hai — plus

7 years ago
Editor's note

FDA gives Mer­ck ‘re­al-time’ OK for Keytru­da, of­fer­ing a peek at the lat­est ex­ten­sion of the agen­cy's da­ta ex­press ...

7 years ago
Pharma

Novo's new tri­al re­sults stoke block­buster hopes, with oral semaglu­tide scor­ing again in Phase II­Ia

7 years ago
R&D

Right on the heels of $150M raise, As­cen­t­age files the lat­est in a rush of HKEX biotech IPOs — but is the mar­ket ...

7 years ago
Financing
China

Ex-CEO at Chi­na Bi­o­log­ic spear­heads $3.9B buy­out of­fer; Sy­neos ac­quires Ki­napse, adding 600 staffers

7 years ago
News Briefing

Hous­ing As­traZeneca's old R&D ef­forts in an­tibi­otics, En­ta­sis files for $86M IPO

7 years ago
Financing
First page Previous page 1016101710181019102010211022 Next page Last page
A service from the Financial Times